Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more
Zealand Pharma A/S (ZLDPF) - Net Assets
Latest net assets as of September 2025: $999.16 Million USD
Based on the latest financial reports, Zealand Pharma A/S (ZLDPF) has net assets worth $999.16 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.63 Billion) and total liabilities ($1.63 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $999.16 Million |
| % of Total Assets | 37.94% |
| Annual Growth Rate | 23.37% |
| 5-Year Change | 632.04% |
| 10-Year Change | 3316.21% |
| Growth Volatility | 116.12 |
Zealand Pharma A/S - Net Assets Trend (2007–2024)
This chart illustrates how Zealand Pharma A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zealand Pharma A/S (2007–2024)
The table below shows the annual net assets of Zealand Pharma A/S from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.62 Billion | +440.97% |
| 2023-12-31 | $1.59 Billion | +95.22% |
| 2022-12-31 | $815.91 Million | -12.06% |
| 2021-12-31 | $927.80 Million | -21.18% |
| 2020-12-31 | $1.18 Billion | -5.28% |
| 2019-12-31 | $1.24 Billion | +11.32% |
| 2018-12-31 | $1.12 Billion | +111.23% |
| 2017-12-31 | $528.47 Million | +89.96% |
| 2016-12-31 | $278.19 Million | +10.29% |
| 2015-12-31 | $252.23 Million | -0.24% |
| 2014-12-31 | $252.83 Million | -20.03% |
| 2013-12-31 | $316.14 Million | -35.61% |
| 2012-12-31 | $491.01 Million | +11.24% |
| 2011-12-31 | $441.40 Million | +8.42% |
| 2010-12-31 | $407.11 Million | +206.27% |
| 2009-12-31 | $132.92 Million | -36.29% |
| 2008-12-31 | $208.63 Million | -13.92% |
| 2007-12-31 | $242.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zealand Pharma A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2840.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $71.02 Million | 0.82% |
| Other Comprehensive Income | $22.39 Million | 0.26% |
| Other Components | $14.68 Billion | 170.37% |
| Total Equity | $8.62 Billion | 100.00% |
Zealand Pharma A/S Competitors by Market Cap
The table below lists competitors of Zealand Pharma A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Siam Cement Public Company Limited
PINK:SCVPF
|
$3.46 Billion |
|
Allreal Holding
SW:ALLN
|
$3.46 Billion |
|
Kyowa Kirin Co. Ltd
PINK:KYKOF
|
$3.46 Billion |
|
BGC Group Inc.
NASDAQ:BGC
|
$3.46 Billion |
|
Impulsora del Desarrollo y el Empleo en América Latina S.A.B. de C.V
MX:IDEALB-1
|
$3.46 Billion |
|
NH Foods Ltd
F:NI6
|
$3.45 Billion |
|
Waystar Holding Corp. Common Stock
NASDAQ:WAY
|
$3.45 Billion |
|
Enerjisa Enerji AS
IS:ENJSA
|
$3.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zealand Pharma A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,592,839,000 to 8,616,742,000, a change of 7,023,903,000 (441.0%).
- Net loss of 1,078,828,000 reduced equity.
- Share repurchases of 351,834,000 reduced equity.
- New share issuances of 8,523,479,000 increased equity.
- Other comprehensive income decreased equity by 316,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.08 Billion | -12.52% |
| Share Repurchases | $351.83 Million | -4.08% |
| Share Issuances | $8.52 Billion | +98.92% |
| Other Comprehensive Income | $-316.00K | -0.0% |
| Other Changes | $-68.60 Million | -0.8% |
| Total Change | $- | 440.97% |
Book Value vs Market Value Analysis
This analysis compares Zealand Pharma A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.52x to 0.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $13.71 | $61.95 | x |
| 2008-12-31 | $11.80 | $61.95 | x |
| 2009-12-31 | $7.52 | $61.95 | x |
| 2010-12-31 | $22.37 | $61.95 | x |
| 2011-12-31 | $19.77 | $61.95 | x |
| 2012-12-31 | $21.60 | $61.95 | x |
| 2013-12-31 | $13.97 | $61.95 | x |
| 2014-12-31 | $11.17 | $61.95 | x |
| 2015-12-31 | $10.94 | $61.95 | x |
| 2016-12-31 | $11.44 | $61.95 | x |
| 2017-12-31 | $18.97 | $61.95 | x |
| 2018-12-31 | $36.37 | $61.95 | x |
| 2019-12-31 | $36.76 | $61.95 | x |
| 2020-12-31 | $30.68 | $61.95 | x |
| 2021-12-31 | $21.64 | $61.95 | x |
| 2022-12-31 | $17.66 | $61.95 | x |
| 2023-12-31 | $28.15 | $61.95 | x |
| 2024-12-31 | $129.70 | $61.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zealand Pharma A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1720.87%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.10x
- Recent ROE (-12.52%) is above the historical average (-38.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -22.69% | -91.79% | 0.23x | 1.09x | $-79.24 Million |
| 2008 | -16.17% | -59.96% | 0.25x | 1.08x | $-54.60 Million |
| 2009 | -56.96% | -299.02% | 0.16x | 1.19x | $-89.00 Million |
| 2010 | -25.70% | -119.78% | 0.19x | 1.11x | $-145.34 Million |
| 2011 | 3.03% | 9.40% | 0.30x | 1.06x | $-30.76 Million |
| 2012 | 7.41% | 16.27% | 0.43x | 1.06x | $-12.73 Million |
| 2013 | -58.10% | -2793.98% | 0.02x | 1.10x | $-215.29 Million |
| 2014 | -25.71% | -42.26% | 0.26x | 2.36x | $-90.27 Million |
| 2015 | -45.18% | -60.72% | 0.30x | 2.52x | $-139.18 Million |
| 2016 | -55.32% | -65.56% | 0.34x | 2.50x | $-181.73 Million |
| 2017 | -51.52% | -194.79% | 0.19x | 1.40x | $-325.12 Million |
| 2018 | 52.07% | 1530.61% | 0.03x | 1.10x | $469.65 Million |
| 2019 | -45.99% | -1382.77% | 0.03x | 1.29x | $-695.81 Million |
| 2020 | -71.93% | -239.65% | 0.18x | 1.64x | $-964.44 Million |
| 2021 | -109.74% | -348.01% | 0.14x | 2.23x | $-1.11 Billion |
| 2022 | -118.35% | -928.60% | 0.07x | 1.89x | $-1.05 Billion |
| 2023 | -44.18% | -205.30% | 0.17x | 1.24x | $-863.02 Million |
| 2024 | -12.52% | -1720.87% | 0.01x | 1.10x | $-1.94 Billion |
Industry Comparison
This section compares Zealand Pharma A/S's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zealand Pharma A/S (ZLDPF) | $999.16 Million | -22.69% | 1.64x | $3.46 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |